Peptide library / Digestive & weight / Ecnoglutide
Ecnoglutide
An investigational weekly GLP-1 receptor agonist developed in China by Sciwind Biosciences.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- Weight loss in obesityLarge trials
- Type 2 diabetesLarge trials
How it is thought to work
Ecnoglutide is a GLP-1 analog designed to favor the signaling pathway linked to blood sugar control and weight loss.
What the evidence shows
Phase 3 trials in Chinese adults reported weight loss and blood sugar results in line with established GLP-1 drugs.
Safety and unknowns
Gastrointestinal effects were the most common.
Regulatory status
Not approved by the FDA. Check China's regulator for current status.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Digestive & weight
Efpeglenatide
In clinical trialsA long-acting GLP-1 receptor agonist that showed heart and kidney benefit in a large trial.
Eloralintide
In clinical trialsAn investigational amylin receptor agonist from Eli Lilly in development for obesity.
Dulaglutide
FDA-approvedA once-weekly GLP-1 receptor agonist used in type 2 diabetes with proven heart benefit.
General information, not medical advice. Do not buy or inject unregulated peptides.